Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
After publication of our article [1] we were notified that the data presented in the upper row of Fig. 7 was inadvertently the least square mean change from baseline (standard error) at Month 6 rather than the overall average of Month 3 and Month 6. The figure legend and discussion of the data in th...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-12-01
|
| Series: | The Journal of Headache and Pain |
| Online Access: | https://doi.org/10.1186/s10194-019-1069-x |
| _version_ | 1818622780597338112 |
|---|---|
| author | Stephen D. Silberstein Virginia L. Stauffer Katie A. Day Sarah Lipsius Maria-Carmen Wilson |
| author_facet | Stephen D. Silberstein Virginia L. Stauffer Katie A. Day Sarah Lipsius Maria-Carmen Wilson |
| author_sort | Stephen D. Silberstein |
| collection | DOAJ |
| description | After publication of our article [1] we were notified that the data presented in the upper row of Fig. 7 was inadvertently the least square mean change from baseline (standard error) at Month 6 rather than the overall average of Month 3 and Month 6. The figure legend and discussion of the data in the text were and are correct. The error was only in the upper row of Fig. 7. The legend for Fig. 7 did not require revision. |
| first_indexed | 2024-12-16T18:30:37Z |
| format | Article |
| id | doaj.art-f9f5249165db4db9abd31d6f43d4fb83 |
| institution | Directory Open Access Journal |
| issn | 1129-2369 1129-2377 |
| language | English |
| last_indexed | 2024-12-16T18:30:37Z |
| publishDate | 2019-12-01 |
| publisher | BMC |
| record_format | Article |
| series | The Journal of Headache and Pain |
| spelling | doaj.art-f9f5249165db4db9abd31d6f43d4fb832022-12-21T22:21:19ZengBMCThe Journal of Headache and Pain1129-23691129-23772019-12-012011210.1186/s10194-019-1069-xCorrection to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)Stephen D. Silberstein0Virginia L. Stauffer1Katie A. Day2Sarah Lipsius3Maria-Carmen Wilson4Jefferson Headache Center, Thomas Jefferson UniversityLilly Research Laboratories, Lilly Corporate CenterLilly Research Laboratories, Lilly Corporate CenterSyneos HealthOchsner Health SystemAfter publication of our article [1] we were notified that the data presented in the upper row of Fig. 7 was inadvertently the least square mean change from baseline (standard error) at Month 6 rather than the overall average of Month 3 and Month 6. The figure legend and discussion of the data in the text were and are correct. The error was only in the upper row of Fig. 7. The legend for Fig. 7 did not require revision.https://doi.org/10.1186/s10194-019-1069-x |
| spellingShingle | Stephen D. Silberstein Virginia L. Stauffer Katie A. Day Sarah Lipsius Maria-Carmen Wilson Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) The Journal of Headache and Pain |
| title | Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) |
| title_full | Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) |
| title_fullStr | Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) |
| title_full_unstemmed | Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) |
| title_short | Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) |
| title_sort | correction to galcanezumab in episodic migraine subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies evolve 1 evolve 2 |
| url | https://doi.org/10.1186/s10194-019-1069-x |
| work_keys_str_mv | AT stephendsilberstein correctiontogalcanezumabinepisodicmigrainesubgroupanalysesofefficacybyhighversuslowfrequencyofmigraineheadachesinphase3studiesevolve1evolve2 AT virginialstauffer correctiontogalcanezumabinepisodicmigrainesubgroupanalysesofefficacybyhighversuslowfrequencyofmigraineheadachesinphase3studiesevolve1evolve2 AT katieaday correctiontogalcanezumabinepisodicmigrainesubgroupanalysesofefficacybyhighversuslowfrequencyofmigraineheadachesinphase3studiesevolve1evolve2 AT sarahlipsius correctiontogalcanezumabinepisodicmigrainesubgroupanalysesofefficacybyhighversuslowfrequencyofmigraineheadachesinphase3studiesevolve1evolve2 AT mariacarmenwilson correctiontogalcanezumabinepisodicmigrainesubgroupanalysesofefficacybyhighversuslowfrequencyofmigraineheadachesinphase3studiesevolve1evolve2 |